Singapore's biomedical sciences landscape

摘要

Singapore's vision is to be the Biopolis of Asia, a leading international biomedical sciences clusteradvancing human health, through the pursuit of excellence in research and development, manufacturingand healthcare delivery. To achieve this, Singapore has built up world-class capabilities across the entirevalue chain from drug discovery, development and clinical research, to manufacturing and healthcaredelivery. In the year 2000, Singapore's Biomedical Sciences (BMS) initiative was launched to establish afocused effort on the development of this sector as the fourth pillar of Singapore's industry cluster,alongside electronics, chemicals and engineering. The BMS initiative covers the Pharmaceutical,Biotechnology, Medical Engineering and Technology and Healthcare Services industries. An integratedstrategy was adopted for the development of the BMS sector, focusing on Human Capital, IntellectualCapital and Industrial Capital, or 3 Cs in short. The first phase of the BMS initiative (2000-2005) put inplace key building blocks by establishing core capabilities in biomedical research, and introducing importanthuman capital and industrial capital development initiatives. For the next phase (2006-2010), we will buildon this foundation and strengthen our capabilities in translational and clinical research to bring discoveriesfrom the bench to the bedside and the marketplace, and ultimately improve human healthcare.